Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080549 | 1.00 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL4536526 | 1.00 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL2417410 | 1.00 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL16055986 | 1.00 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL6890333 | 1.00 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL5491671 | 0.96 | CA2 (0.48) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL15018263 | 0.95 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL11159529 | 0.95 | CA2 (0.52) | CA2LMNADNM1MAPK1GRIK1 | |
| SCHEMBL16098322 | 0.95 | CA2 (0.47) | CA2LMNAGRIK1GRIK2FFAR1 | |
| SCHEMBL16097848 | 0.95 | CA2 (0.47) | CA2LMNAGRIK1GRIK2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791099-B1 | PRODUCTION OF ACETIC ACID WITH ENHANCED CATALYST STABILITY | CELANESE INT CORP (US) | 2017-02-01 | — | — | EP | disclosed |
| US-8916727-B2 | Production of acetic acid with enhanced catalyst stability | CELANESE INTERNATIONAL CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2791099-A1 | PRODUCTION OF ACETIC ACID WITH ENHANCED CATALYST STABILITY | Celanese International Corporation (US) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014143324-A1 | ASYMMETRIC PHOSPHONIUM HALOALUMINATE IONIC LIQUID COMPOSITIONS | CYTEC INDUSTRIES INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130184491-A1 | Production of Acetic Acid with Enhanced Catalyst Stability | CELANESE INTERNATIONAL CORPORATION (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013090720-A1 | PRODUCTION OF ACETIC ACID WITH ENHANCED CATALYST STABILITY | CELANESE INTERNATIONAL CORPORATION (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012064703-A1 | DOPO-DERIVED FLAME RETARDANT AND SYNTHETIC HYDROGARNETS FOR EPOXY RESIN COMPOSITIONS | ALBEMARLE CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| US-6680286-B1 | CONTAINING AN ORGANIC POLYELECTROLYTE BUILDER, QUATERNARY AMMONIUM ACRYLIC POLYMERS, WHICH ARE ESPECIALLY USEFUL FOR WASHING CLOTHES | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184491-A1 | Production of Acetic Acid with Enhanced Catalyst Stability | ACADM, CA6, ADH5 | CA2 30/4885LMNA 4514/4885DNM1 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.